POM-V Prescription Required Companion Animal

Fugasol 10 mg/ml Oral Solution for Cats

Active ingredient: Itraconazole

Form

Liquid

Species

Cats

Manufacturer

CP Pharma Handelsgesellschaft mbH

VMD MA No.

20916/3003

What it's used for

Treatment of dermatophytosis caused by Microsporum canis.

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Itraconazole

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Fugasol 10 mg/ml Oral Solution for Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Treatment of dermatophytosis caused by Microsporum canis.

Administer 5 mg of itraconazole per kg body weight once daily, equivalent to 0.5 ml
of the veterinary medicinal product per kg body weight once daily. The solution should
be administered directly into the mouth by means of a dosing syringe.
The dosage regime is 0.5 ml/kg/day for 3 alternate periods of 7 consecutive days,

each time with 7 days without treatment in between.
7 Days7 Days7 Days7 Days7 DaysTreatmentNo treatmentTreatmentNo treatmentTreatment
The dosing syringe shows graduations per 100 gram of body weight. Fill the syringe

by pulling the plunger until it reaches the graduation corresponding to the correct

body
weight of the cat.
When administering the veterinary medicinal product to kittens, the administrator
should be careful not

to administer more than the recommended dose/weight. For
kittens weighing less

than 0.5 kg, a 1 ml syringe which allows proper dosing should
be used.
Treat the animal by slowly and gently injecting the liquid into the mouth, allowing

the
cat to swallow the veterinary medicinal product.
After dosing, the syringe should be removed from the bottle, washed and dried and

the cap should be screwed back on tightly.
Data in humans shows that food intake may result in lower drug absorption.

Therefore, it is recommended to administer the veterinary medicinal product by
preference between

meals.
In some cases, a prolonged time between clinical and mycological cure may be

observed. In cases where a positive culture is obtained 4 weeks after the end of

administration, the treatment should be repeated once at the same dosage regimen.

In such cases where the cat is also immunosuppressed, treatment should be repeated

and the underlying disease addressed.
AN: 02085/2024 and 02086/2024

Do not use
- in cases of hypersensitivity to itraconazole, to other azoles or any of the excipients.
AN: 02085/2024 and 02086/2024
- in cases of impaired liver or kidney function.
- in pregnant and lactating queens: see section 3.7.

Cats:
Common
(1 to 10 animals / 100 animals
treated):
Vomiting
, diarrhoea
, increased salivation
Anorexia
, depression
, apathy
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Elevated liver enzymes
2,4
Icterus
3,4
These effects are usually mild and transient.
Transient
Associated with elevated liver enzymes
If clinical signs suggestive of liver dysfunction develop, treatment should be
discontinued immediately.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or the national competent authority via the
national reporting system. See the package leaflet for respective contact details.

Some cases of feline dermatophytosis can be difficult to cure, especially in catteries.
Cats treated with itraconazole can still infect other cats with M. canis as long as they
are not mycologically cured. It is therefore advised to minimise the risk of re-infection
or spread of infection by keeping healthy animals (including dogs as they can also be
infected by M. canis) separate from cats that are being treated. Cleaning and
disinfection of the environment with appropriate fungicidal products is highly
recommended – especially in case of group problems.
When clipping the hair of infected cats, the advice of the veterinarian should be
sought first.
Clipping of the hair coat is considered useful because it removes infected hairs,
stimulates new hair growth and hastens recovery. It is strongly recommended that
clipping is performed by a veterinarian. In cases with limited lesions, hair clipping can
be limited to the lesions only, whereas in cats with generalised dermatophytosis it is
recommended to clip the entire hair coat. Care should be taken not to cause trauma
to the underlying skin during clipping. It is recommended that disposable, protective
clothing and gloves are worn during the clipping of the affected animals. The clipping
of the hair should be performed in a well ventilated room which can be disinfected
after clipping. The hairs should be disposed of appropriately and all instruments,
clippers etc. should be disinfected.
Treatment of dermatophytosis should not be limited to treatment of the infected
animal(s). It should also include disinfection of the environment with appropriate
fungicidal products, since
months. Other measures such as frequent
vacuuming, disinfection of grooming equipment and removal of all potentially
contaminated material that cannot be disinfected will minimise the risk of re-infection
or spread of infection. Disinfection and vacuuming should be continued for an
extended period after the cat is clinically cured, but vacuuming should be limited to
surfaces, which may not be cleaned with a damp cloth. All other surfaces should be
cleaned with a damp cloth. Any cloth used for cleaning should be washed and
disinfected or disposed of and the used vacuum cleaner bag should be disposed of.
Measures to prevent introduction of M. canis into groups of cats may include isolation
of new cats, isolation of cats returning from shows or breeding, exclusion of visitors
and periodic monitoring by Wood's lamp or by culturing for M. canis.
In refractory cases the possibility of an underlying disease should be considered.
Frequent and repeated use of an antimycotic may result in the induction of resistance
to antimycotics of the same class.
AN: 02085/2024 and 02086/2024

Special precautions for safe use in the target species:
Cats suffering from dermatophytosis, but also in poor general condition and/or

suffering from additional diseases or impaired immunological response should be

monitored closely during treatment. Because of their condition, this category of

animals may be more sensitive to the development of adverse effects. In case of a

serious adverse effect, treatment should be interrupted and supportive care therapy

(fluid therapy) should be initiated if necessary. If clinical signs suggestive of liver

dysfunction develop, treatment should be discontinued immediately. It is very

important to monitor liver enzymes in animals showing signs of liver dysfunction.
In humans, itraconazole has been associated with heart failure due to a negative

inotropic effect. Cats suffering from heart diseases should be carefully monitored and

the treatment should be withdrawn if the clinical signs deteriorate.
Use of the product should be based on identification and susceptibility testing of the
target pathogen(s). If this is not possible, therapy should be based on epidemiological
information and knowledge of susceptibility of the target pathogens at farm level, or
at local/regional level.
Use of the product should be in accordance with official, national and regional
antimicrobial policies.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
M. canis

dermatophytosis is a zoonotic disease. Therefore, wear latex gloves when
clipping

hair of infected cats, when handling the animal during treatment or when
cleaning

the syringe. If a suspected lesion occurs on a human, consult a physician.
This veterinary medicinal product may cause skin and/or eye irritation. Avoid contact
with skin and eyes. Wash hands and exposed skin after use. In case of accidental
contact with eyes, rinse

thoroughly with water. In case of persistent pain or irritation,
seek medical advice and show the label or package leaflet to the physician.
This veterinary medicinal product may be harmful after accidental ingestion by
children. Do not leave the filled syringe unattended. In case of

accidental ingestion,
rinse mouth with water, seek medical advice immediately and show the package
leaflet or the label to the physician.
This veterinary medicinal product may cause hypersensitivity reactions. People with
known hypersensitivity to itraconazole or propylene glycol should avoid contact with
the veterinary medicinal product. Wash hands after use.
Special precautions for the protection of the environment:
Not applicable.
AN: 02085/2024 and 02086/2024

Vomiting, hepatic and renal disorders were seen after concomitant treatment of
itraconazole and cefovecin. Symptoms like motor incoordination, faecal retention and
dehydration are observed when tolfenamic acid and itraconazole are given
simultaneously. Co-administration of the veterinary medicinal product and these
drugs, in absence of data in cats, should be avoided.
In human medicine, interactions between itraconazole and certain other drugs have
been described, resulting from interactions with cytochrome P450 3A4 (CYP3A4) and
P-glycoproteins (PgP). This may result in increased plasma concentrations of e.g.
oral midazolam, cyclosporin, digoxin, chloramphenicol, ivermectin, or
methylprednisolone. The increased plasma levels can prolong the duration of effects
as well as side effects. Itraconazole may also increase the serum level of oral
antidiabetic agents, which may result in hypoglycaemia.
On the other hand, some drugs, e.g. barbiturates or phenytoin can increase the rate
of metabolism of itraconazole, resulting in a decreased bioavailability, hence a
decreased efficacy. As itraconazole requires an acidic environment for maximal
absorption, antacids cause a marked reduction in absorption. Concomitant use of
erythromycin can increase the plasma concentration of itraconazole.
AN: 02085/2024 and 02086/2024
Interactions in humans between itraconazole and calcium antagonists have also
been reported. These drugs might have additive negative inotropic effects to the
heart.
It is not known to what extent these interactions are relevant for cats, but in the
absence of data, co-administration of the veterinary medicinal product and these
drugs should be avoided.

This veterinary medicinal product does not require any special temperature storage
conditions.
Keep the container tightly closed.

Not applicable.
4.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.